EXACT Sciences Corp. (EXAS)

117.04
0.83 0.70
NASDAQ : Health Technology
Prev Close 117.87
Open 117.80
Day Low/High 114.54 / 118.63
52 Wk Low/High 53.06 / 123.99
Volume 775.73K
Avg Volume 1.57M
Exchange NASDAQ
Shares Outstanding 129.49M
Market Cap 15.44B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short-Seller Left Goes Long on Invitae With $100 Target

Short-Seller Left Goes Long on Invitae With $100 Target

Citron analyst sees 'indestructible moat' around genetic-testing company's business.

Exact Sciences Is Poised to Test New Highs on the Charts

Exact Sciences Is Poised to Test New Highs on the Charts

Here's how to trade the stock right now.

Don't Fight the Fed: Cramer's 'Mad Money' Recap (Monday 7/29/19)

Don't Fight the Fed: Cramer's 'Mad Money' Recap (Monday 7/29/19)

Jim Cramer talks about what investors need to do ahead of an expected rate cut and amid earnings and trade upheaval.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.

NEW YORK, July 29, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc.

Exact Sciences Reaches Deal to Acquire Genomic Health for $2.8 Billion

Exact Sciences Reaches Deal to Acquire Genomic Health for $2.8 Billion

Cancer diagnostics company Exact Sciences will acquire healthcare company Genomic Health for about $2.8 billion.

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.

Second-quarter Revenue Increased 94 Percent To $200 Million And Cologuard Test Volume Increased 93 Percent To 415,000

Second-quarter Revenue Increased 94 Percent To $200 Million And Cologuard Test Volume Increased 93 Percent To 415,000

- Estimated Cologuard® market share increased to 5.7 percent during the second quarter

Exact Sciences And Genomic Health To Combine, Creating Leading Global Cancer Diagnostics Company

Exact Sciences And Genomic Health To Combine, Creating Leading Global Cancer Diagnostics Company

Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth

Exact Sciences in Talks to Buy Genomic Health - Report

Exact Sciences in Talks to Buy Genomic Health - Report

Cancer diagnostics company Exact Sciences is in advanced talks to acquire Genomic Health for about $2.8 billion to strengthen its cancer-testing offerings, according to Bloomberg.

Exact Sciences Designated A Great Place To Work-Certified™ Company In 2019

Exact Sciences Designated A Great Place To Work-Certified™ Company In 2019

Hundreds of open positions offer opportunity to join growing company

Exact Sciences To Host Annual Meeting, Second-quarter 2019 Results Webcasts And Calls

Exact Sciences To Host Annual Meeting, Second-quarter 2019 Results Webcasts And Calls

MADISON, Wis., July 9, 2019 /PRNewswire/ -- Exact Sciences Corp.

Exact Sciences Advances Fight Against Colorectal Cancer With Opening Of New Laboratory

Exact Sciences Advances Fight Against Colorectal Cancer With Opening Of New Laboratory

Company's total lab processing capacity expected to reach 7 million by end of year

Wendy's, Zoetis, New Age Beverages: 'Mad Money' Lightning Round

Wendy's, Zoetis, New Age Beverages: 'Mad Money' Lightning Round

A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.

Trump's Change of Heart: Cramer's 'Mad Money' Recap (Monday 6/3/19)

Trump's Change of Heart: Cramer's 'Mad Money' Recap (Monday 6/3/19)

By going after friendly trading partners and big tech Trump is forcing Wall Street to re-calibrate and lower valuations, Jim Cramer says.

Exact Sciences To Participate In June Investor Conferences

Exact Sciences To Participate In June Investor Conferences

MADISON, Wis., May 31, 2019 /PRNewswire/ -- Exact Sciences Corp.

Exact Sciences Advances Pipeline Capabilities With Mayo Clinic

Exact Sciences Advances Pipeline Capabilities With Mayo Clinic

Early data on pancreatic cancer detection presented at Digestive Disease Week® 2019

Exact Sciences Presents New Data Reinforcing Performance Of Cologuard®

Exact Sciences Presents New Data Reinforcing Performance Of Cologuard®

Researchers to Present Real-World Findings at Digestive Disease Week® 2019

Noteworthy Friday Option Activity: EXAS, CWH, BCRX

Noteworthy Friday Option Activity: EXAS, CWH, BCRX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in EXACT Sciences Corp. , where a total volume of 10,929 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares).

Exact Sciences To Participate In May Investor Conferences

Exact Sciences To Participate In May Investor Conferences

MADISON, Wis., May 1, 2019 /PRNewswire/ -- Exact Sciences Corp.

First-quarter Revenue And Cologuard Test Volume Increased 79 Percent To $162 Million And 334,000, Respectively

First-quarter Revenue And Cologuard Test Volume Increased 79 Percent To $162 Million And 334,000, Respectively

- Estimated Cologuard market share increased to 4.6 percent during the first quarter

Exact Sciences Schedules First-quarter 2019 Earnings Call

Exact Sciences Schedules First-quarter 2019 Earnings Call

MADISON, Wis., Apr.

Kathleen Sebelius Appointed To Exact Sciences Board

Kathleen Sebelius Appointed To Exact Sciences Board

Former Health and Human Services Secretary brings government and health care expertise to company working to detect cancer earlier

Exact Sciences Looks Vulnerable: Protect Longs

Exact Sciences Looks Vulnerable: Protect Longs

Shares of Exact Sciences has been on the upswing, but the stock price of the cancer screening test firm may be vulnerable.

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

Jim Cramer's watching six stocks to determine when the selling will end.

Exact Sciences Announces Offering Of $600 Million Convertible Senior Notes Due 2027

Exact Sciences Announces Offering Of $600 Million Convertible Senior Notes Due 2027

MADISON, Wis., March 5, 2019 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant...

Exact Sciences To Participate In March Investor Conferences

Exact Sciences To Participate In March Investor Conferences

MADISON, Wis., March 1, 2019 /PRNewswire/ -- Exact Sciences Corp.

Cologuard Helps Screen Two Million People For Colorectal Cancer

Cologuard Helps Screen Two Million People For Colorectal Cancer

Exact Sciences Announces Milestone Ahead of Cologuard Classic, National Colorectal Cancer Awareness Month

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

TheStreet Quant Rating: C- (Hold)